following a full submission:
durvalumab (Imfinzi®) is accepted for use within NHSScotland.
Indication under review: As monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy.
In a randomised, double blind phase III study, durvalumab significantly improved progression free and overall survival compared with placebo in patients with LS SCLC who had not progressed following concurrent chemoradiotherapy.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- durvalumab (Imfinzi)
- SMC ID:
- SMC2818
- Indication:
Treatment of adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 May 2026